Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.

Hirotsugu UemuraYoshihiko TomitaNorio NonomuraKenji YoshizakiTakafumi NakaoNobuo Shinohara

Published in: International journal of clinical oncology (2022)

The safety profile of nivolumab monotherapy in Japanese patients with advanced RCC was similar to that in the phase 3 CheckMate 025 trial. No new safety signals were observed in this study.

Keyphrases

renal cell carcinoma
randomized controlled trial
systematic review
public health
clinical trial
study protocol
phase ii